Cite
Simonds EF, Lu ED, Badillo O, et al. Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma. J Immunother Cancer. 2021;9(6)doi: 10.1136/jitc-2020-002181.
Simonds, E. F., Lu, E. D., Badillo, O., Karimi, S., Liu, E. V., Tamaki, W., Rancan, C., Downey, K. M., Stultz, J., Sinha, M., McHenry, L. K., Nasholm, N. M., Chuntova, P., Sundström, A., Genoud, V., Shahani, S. A., Wang, L. D., Brown, C. E., Walker, P. R., Swartling, F. J., Fong, L., Okada, H., Weiss, W. A., & Hellström, M. (2021). Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma. Journal for immunotherapy of cancer, 9(6), . https://doi.org/10.1136/jitc-2020-002181
Simonds, Erin F, et al. "Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma." Journal for immunotherapy of cancer vol. 9,6 (2021). doi: https://doi.org/10.1136/jitc-2020-002181
Simonds EF, Lu ED, Badillo O, Karimi S, Liu EV, Tamaki W, Rancan C, Downey KM, Stultz J, Sinha M, McHenry LK, Nasholm NM, Chuntova P, Sundström A, Genoud V, Shahani SA, Wang LD, Brown CE, Walker PR, Swartling FJ, Fong L, Okada H, Weiss WA, Hellström M. Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma. J Immunother Cancer. 2021 Jun;9(6). doi: 10.1136/jitc-2020-002181. PMID: 34083417; PMCID: PMC8183210.
Copy
Download .nbib